Pharmaceutical - Anti-virals, Europe

Filter

Current filters:

Anti-viralsEurope

Popular Filters

HIV therapy Rezolsta approved by EC

HIV therapy Rezolsta approved by EC

25-11-2014

Belgium-based Janssen-Cilag International NV, a subsidiary of US health care giant Johnson & Johnson,…

Anti-viralsEuropeJanssen-CilagPharmaceuticalPrezistaRegulation

EMA unit backs new hep C drugs Exviera and Viekirax from AbbVie

EMA unit backs new hep C drugs Exviera and Viekirax from AbbVie

21-11-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

AbbVieAnti-viralsEuropeExvieraPharmaceuticalRegulationViekirax

EFPIA and IMI launch 280 million-euro Ebola program, calling for proposals

EFPIA and IMI launch 280 million-euro Ebola program, calling for proposals

10-11-2014

The European Federation of Pharmaceutical Industries and Associations, its specialized group Vaccines…

Anti-viralsEuropeFinancialPharmaceuticalResearchUSA

EMA moves further to push Ebola treatments development

EMA moves further to push Ebola treatments development

23-10-2014

During the past months, the European Medicines Agency has put in place a system to give the best possible…

Anti-viralsEuropePharmaceuticalRegulationResearchVaccines

EMA urging firms with Ebola candidates to seek orphan status

21-10-2014

The European Medicines Agency is aiming to encourage developers of treatments or vaccines against Ebola…

Anti-viralsEuropePharmaceuticalRare diseasesRegulationResearchUSA

EU marketing authorization for ViiV Healthcare HIV drug Triumeq

EU marketing authorization for ViiV Healthcare HIV drug Triumeq

03-09-2014

The European Commission has granted marketing authorization for ViiV Healthcare’s Triumeq (dolutegravir…

Anti-viralsEuropeGlaxoSmithKlinePharmaceuticalRegulationTriumeqViiV Healthcare

Bristol-Myers’ hep C drug Daklinza approved in Europe

Bristol-Myers’ hep C drug Daklinza approved in Europe

27-08-2014

US pharma major Bristol-Myers Squibb says that the European Commission has approved Daklinza (daclatasvir),…

Anti-viralsBristol-Myers SquibbDaklinzaEuropeGilead SciencesPharmaceuticalRegulationSovaldi

Drug-treated hepatitis C population to more than double by 2016

Drug-treated hepatitis C population to more than double by 2016

16-07-2014

The hepatitis C virus population is already large, with 2 million diagnosed, chronically infected cases…

Anti-viralsCytokinesDaklinzaDecision Resources GroupEuropeHepatitis CInterferonJapanMarkets & MarketingPharmaceuticalUSA

Positive CHMP opinion for Janssen’s simeprevir for chronic hepatitis C

24-03-2014

US health care giant Johnson & Johnson’s European subsidiary Janssen R&D Ireland has received a positive…

Anti-viralsEuropeJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalRegulationsimeprevir

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

17-03-2014

The president of pharma giant Merck & Co’s (NYSE: MRK) operations in Europe and Canada Bruno Strigini…

Anti-viralsCanadaDiabetesEuropeInterviewsMerck & CoMK-3475OncologyPharmaceuticalRegulationUKVaccines

ViiV Healthcare’s new HIV medicine Tivicay is approved in Europe

21-01-2014

The European Commission has approved Tivicay (dolutegravir) made by Viiv Healthcare for use in combination…

Anti-viralsEuropePharmaceuticalResearchTivicayViiV Healthcare

Tivicay set to become leading HIV treatment by 2016

Tivicay set to become leading HIV treatment by 2016

15-01-2014

Antiretroviral drug Tivicay (dolutegravir) is set to become the leading integrase inhibitor for the treatment…

Anti-viralsAsia-PacificEuropeIsentressJanssenMarkets & MarketingMerck & CoPharmaceuticalPrezistaTivicayUSAViiV Healthcare

Back to top